Medicine guide
Recarbrio
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Imipenem;cilastatin;relebactam
- Made by
- Merck Sharp & Dohme B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Recarbrio is indicated for:- Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1).- Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.- Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Merck Sharp & Dohme B.V. |
|---|---|
| Active substance | Imipenem;cilastatin;relebactam |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J01DH56 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2020-02-13 |
| Last updated by the regulator | 2026-01-26 |
| EMA product number | EMEA/H/C/004808 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).